

The listing of claims presented below replaces all prior versions and listing of claims in the application.

Listing of claims:

1. (Original)            A double-stranded RNA molecule capable of suppressing the expression of a target gene in a cell by RNAi, which is designed such that one or more nucleotides in order from the 3'-end of the sense strand of double-stranded part in said RNA molecule are not complementary to the antisense strand,

                                 wherein the sense strand of the double-stranded part has adequate number of nucleotides which are complementary to the antisense strand for enabling the hybridization of both strands in said cell.

2. (Original)            The double-stranded RNA molecule according to claim 1, wherein the number of the nucleotides which are not complementary to the antisense strand in order from the 3'-end of the sense strand of the double-stranded part is 1 to 4.

3. (Original)            The double-stranded RNA molecule according to claim 1, wherein the number of the nucleotides which are not complementary to the antisense strand in order from the 3'-end of the sense strand of the double-stranded part is 2.

4. (Original)            The double-stranded RNA molecule according to claim 1, which is designed such that one additional nucleotide located at position 11-13 from the 3'-end of the sense strand of the double-stranded part is not complementary to the antisense strand.

5. (Original) The double-stranded RNA molecule according to claim 4, which is designed such that a nucleotide located at position 12 from the 3'-end of the sense strand of the double-stranded part is not complementary to the antisense strand.

6. (Currently Amended) The double-stranded RNA molecule according to claim 1, which is designed such that one additional nucleotide located at nucleotide position 1-3 in the 5'- or 3'-direction from a site on the sense strand of the double-stranded part is not complementary to the antisense strand, the site corresponding to the cleavage site of the target gene transcription product by RISC.

7. (Currently Amended) The double-stranded RNA molecule according to claim 1, which is designed such that one additional nucleotide located at nucleotide position 1-3 in the 5'-direction from the nucleotide in the center of the sense strand of the double-stranded part is not complementary to the antisense strand when the double-stranded part of the sense strand has an odd number of nucleotides, and that one additional nucleotide located at nucleotide position 1-3 in the 5'-direction from the nucleotide at the 3'-side of the center of the sense strand of the double-stranded part is not complementary to the antisense strand when the double-stranded part of the sense strand has an even number of nucleotides.

8. (Currently Amended) The double-stranded RNA molecule according to claim 1, which is designed such that one additional nucleotide located at nucleotide position 2 in the 5'-direction from the nucleotide in the center of the sense strand of the double-stranded part is not complementary to the antisense strand when the double-stranded part of the sense strand has an odd number of nucleotides, and that one additional nucleotide located at nucleotide position 2

in the 5'-direction from the nucleotide at the 3'-side of the center of the sense strand of the double-stranded part is not complementary to the antisense strand when the double-stranded part of the sense strand has an even number of nucleotides.

9. (Original) The double-stranded RNA molecule according to claim 1, which does not induce double-stranded RNA-dependent protein kinase or 2',5'-oligoadenylate synthetase in a mammalian cell.

10. (Currently Amended) The double-stranded RNA molecule according to claim 9, ~~which~~ wherein each strand has a strand length of 29 or less nucleotides.

11. (Original) A double-stranded RNA molecule capable of suppressing the expression of a target gene in a cell by RNAi, which is designed such that one or more nucleotides in order from the 5'-end of the sense strand of double-stranded part in said RNA molecule are not complementary to the antisense strand,

wherein the sense strand of the double-stranded part has adequate number of nucleotides which are complementary to the antisense strand for enabling the hybridization of both strands in said cell.

12. (Original) The double-stranded RNA molecule according to claim 11, wherein the number of the nucleotides which are not complementary to the antisense strand in order from the 5'-end of the sense strand of the double-stranded part is 1 to 4.

13. (Original) The double-stranded RNA molecule according to claim 11,

wherein the number of the nucleotides which are not complementary to the antisense strand in order from the 5'-end of the sense strand of the double-stranded part is 2.

14. (Original)                      The double-stranded RNA molecule according to claim 11, which is designed such that one or more additional nucleotides in order from the 3'-end of the sense strand of the double-stranded part are not complementary to the antisense strand.

15. (Original)                      The double-stranded RNA molecule according to claim 14, wherein the number of the nucleotides which are not complementary to the antisense strand in order from the 3'-end of the sense strand of the double-stranded part is 1 to 4.

16. (Original)                      The double-stranded RNA molecule according to claim 14, wherein the number of the nucleotides which are not complementary to the antisense strand in order from the 3'-end of the sense strand of the double-stranded part is 2.

17. (Original)                      The double-stranded RNA molecule according to claim 11, which is designed such that one additional nucleotide located at position 11-13 from the 3'-end of the sense strand of the double-stranded part is not complementary to the antisense strand.

18. (Original)                      The double-stranded RNA molecule according to claim 17, which is designed such that a nucleotide located at position 12 from the 3'-end of the sense strand of the double-stranded part is not complementary to the antisense strand.

19. (Currently Amended)      The double-stranded RNA molecule according to claim 11, which

is designed such that one additional nucleotide located at nucleotide position 1-3 in the 5'- or 3'-direction from a site on the sense strand of the double-stranded part is not complementary to the antisense strand, the site corresponding to the cleavage site of the target gene transcription product by RISC.

20. (Currently Amended) The double-stranded RNA molecule according to claim 11, which is designed such that one additional nucleotide located at nucleotide position 1-3 in the 5'-direction from the nucleotide in the center of the sense strand of the double-stranded part is not complementary to the antisense strand when the double-stranded part of the sense strand has an odd number of nucleotides, and that one additional nucleotide located at nucleotide position 1-3 in the 5'-direction from the nucleotide at the 3'-side of the center of the sense strand of the double-stranded part is not complementary to the antisense strand when the double-stranded part of the sense strand has an even number of nucleotides.

21. (Currently Amended) The double-stranded RNA molecule according to claim 11, which is designed such that one additional nucleotide located at nucleotide position 2 in the 5'-direction from the nucleotide in the center of the sense strand of the double-stranded part is not complementary to the antisense strand when the double-stranded part of the sense strand has an odd number of nucleotides, and that one additional nucleotide located at nucleotide position 2 in the 5'-direction from the nucleotide at the 3'-side of the center of the sense strand of the double-stranded part is not complementary to the antisense strand when the double-stranded part of the sense strand has an even number of nucleotides.

22. (Original) The double-stranded RNA molecule according to claim 11,

which does not induce double-stranded RNA-dependent protein kinase or 2',5'-oligoadenylate synthetase in a mammalian cell.

23. (Currently Amended) The double-stranded RNA molecule according to claim 22, ~~which~~ wherein each strand has a strand length of 29 or less nucleotides.

24. (Withdrawn) A method for suppressing the expression of a target gene in a cell, comprising a step of introducing the double-stranded RNA molecule according to ~~of~~ claims 1 into the cell.

25. (Withdrawn) The method according to claim 24, wherein the cell is a mammalian cell.

26. (Previously Presented) A vector comprising both of a DNA encoding the sense strand of the double-stranded RNA molecule according to claim 1 and a DNA encoding the antisense strand of said RNA molecule.

27. (Withdrawn) A method for suppressing the expression of a target gene in a cell, comprising a step of introducing a combination of a vector containing a DNA encoding the sense strand of the double-stranded RNA molecule capable of suppressing the expression of a target gene in a cell by RNAi, which is designed such that one or more nucleotides in order from the 3'-end of the sense strand of double-stranded part in said RNA molecule are not complementary to the antisense strand, wherein the sense strand of the double-stranded part has adequate number of nucleotides which are complementary to the antisense strand for enabling

the hybridization of both strands in said cell and a vector containing a DNA encoding the antisense strand of said RNA molecule, or a vector according to claim 26, into the cell.

28. (Withdrawn)                      The method according to claim 27, wherein the cell is a mammalian cell.

29. (Cancel)

30. (Cancel)